Merck Expands Bengaluru Facility to Strengthen Global Filtration Supply Chain

The investment is designed to enhance the reliability of supply for both domestic and global customers, particularly for products essential to manufacturing life-saving medicines and vaccines.

Merck has expanded its manufacturing facility in Peenya, Bengaluru, introducing new production lines for filtration hardware systems in 2025 and Pellicon® 2 Ultrafiltration Cassettes in 2026.

The investment is designed to enhance the reliability of supply for both domestic and global customers, particularly for products essential to manufacturing life-saving medicines and vaccines.

“These products are essential to producing life-saving medicines and vaccines,” said Tony Qiu, Head of APAC Operations, Life Science Business, Merck. “By expanding manufacturing in India, we are strengthening global supply chains while also supporting local innovation and skills development.”

Pellicon® 2 ultrafiltration cassettes are extensively used in bioprocessing and downstream purification workflows, enabling high-quality filtration across pharmaceutical and life sciences applications. The Peenya facility has served as a global hub for filtration hardware production since 2006 and has gradually expanded its capabilities, including consumables manufacturing such as prefilter cartridges introduced in 2022.

The latest expansion reinforces India’s strategic importance in Merck’s global manufacturing network. It aligns with government initiatives under the Make in India program to bolster advanced manufacturing, foster local value creation, and support skills development in healthcare and life sciences.

Merck’s investment in Bengaluru is expected to strengthen the supply chain for critical pharmaceutical products while supporting technological innovation and local employment in advanced manufacturing sectors.

Stay tuned for more such updates on Digital Health News